Mark Breidenbach
Stock Analyst at Oppenheimer
(2.40)
# 1,425
Out of 4,667 analysts
63
Total ratings
33.33%
Success rate
4.43%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Breidenbach
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Maintains: Outperform | $27 → $30 | $22.64 | +32.51% | 4 | Sep 4, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $14 → $13 | $2.05 | +534.15% | 5 | May 21, 2024 | |
| EPIX ESSA Pharma | Reiterates: Outperform | $17 | $1.73 | +882.66% | 5 | Dec 13, 2023 | |
| ARVN Arvinas | Reiterates: Outperform | $95 | $22.69 | +318.69% | 6 | Aug 9, 2023 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $2.04 | +1,125.49% | 3 | Aug 8, 2023 | |
| CUE Cue Biopharma | Assumes: Outperform | $10 | $1.09 | +817.43% | 6 | Jun 26, 2023 | |
| MCRB Seres Therapeutics | Assumes: Outperform | $12 | $0.81 | +1,374.38% | 4 | Jun 26, 2023 | |
| BLRX BioLineRx | Reiterates: Outperform | $4 | $0.55 | +633.68% | 1 | May 25, 2023 | |
| CGEN Compugen | Maintains: Outperform | $8 → $7 | $1.43 | +389.51% | 7 | May 16, 2023 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $36 → $32 | $1.96 | +1,532.65% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $13 | $0.29 | +4,382.76% | 3 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $15 | $8.14 | +84.28% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $120 | $1.44 | +8,205.65% | 4 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $23 | $1.07 | +2,049.53% | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $225 → $195 | $0.21 | +93,201.44% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $135 | $0.30 | +44,454.46% | 3 | Dec 13, 2019 |
Nurix Therapeutics
Sep 4, 2024
Maintains: Outperform
Price Target: $27 → $30
Current: $22.64
Upside: +32.51%
Allogene Therapeutics
May 21, 2024
Maintains: Outperform
Price Target: $14 → $13
Current: $2.05
Upside: +534.15%
ESSA Pharma
Dec 13, 2023
Reiterates: Outperform
Price Target: $17
Current: $1.73
Upside: +882.66%
Arvinas
Aug 9, 2023
Reiterates: Outperform
Price Target: $95
Current: $22.69
Upside: +318.69%
Immuneering
Aug 8, 2023
Reiterates: Outperform
Price Target: $25
Current: $2.04
Upside: +1,125.49%
Cue Biopharma
Jun 26, 2023
Assumes: Outperform
Price Target: $10
Current: $1.09
Upside: +817.43%
Seres Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $12
Current: $0.81
Upside: +1,374.38%
BioLineRx
May 25, 2023
Reiterates: Outperform
Price Target: $4
Current: $0.55
Upside: +633.68%
Compugen
May 16, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $1.43
Upside: +389.51%
Caribou Biosciences
Mar 10, 2023
Maintains: Outperform
Price Target: $36 → $32
Current: $1.96
Upside: +1,532.65%
Mar 3, 2023
Maintains: Outperform
Price Target: $15 → $13
Current: $0.29
Upside: +4,382.76%
Mar 1, 2023
Maintains: Outperform
Price Target: $25 → $15
Current: $8.14
Upside: +84.28%
Oct 18, 2022
Maintains: Outperform
Price Target: $90 → $120
Current: $1.44
Upside: +8,205.65%
Apr 26, 2021
Initiates: Outperform
Price Target: $23
Current: $1.07
Upside: +2,049.53%
May 12, 2020
Maintains: Outperform
Price Target: $225 → $195
Current: $0.21
Upside: +93,201.44%
Dec 13, 2019
Upgrades: Outperform
Price Target: $135
Current: $0.30
Upside: +44,454.46%